|
Gene: HGF |
Gene summary for HGF |
Gene summary. |
Gene information | Species | Human | Gene symbol | HGF | Gene ID | 3082 |
Gene name | hepatocyte growth factor | |
Gene Alias | DFNB39 | |
Cytomap | 7q21.11 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | P14210 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3082 | HGF | ATC12 | Human | Thyroid | ATC | 1.06e-50 | 1.26e+00 | 0.34 |
3082 | HGF | ATC13 | Human | Thyroid | ATC | 2.48e-11 | 2.29e-01 | 0.34 |
3082 | HGF | ATC4 | Human | Thyroid | ATC | 5.56e-59 | 1.47e+00 | 0.34 |
3082 | HGF | ATC5 | Human | Thyroid | ATC | 2.61e-10 | 2.60e-01 | 0.34 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ATC: Anaplastic thyroid cancer | |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:200123335 | Thyroid | ATC | regulation of apoptotic signaling pathway | 206/6293 | 356/18723 | 2.81e-21 | 5.92e-19 | 206 |
GO:000697934 | Thyroid | ATC | response to oxidative stress | 246/6293 | 446/18723 | 2.98e-21 | 6.09e-19 | 246 |
GO:001050632 | Thyroid | ATC | regulation of autophagy | 180/6293 | 317/18723 | 1.34e-17 | 1.46e-15 | 180 |
GO:001056334 | Thyroid | ATC | negative regulation of phosphorus metabolic process | 234/6293 | 442/18723 | 2.30e-17 | 2.31e-15 | 234 |
GO:006219734 | Thyroid | ATC | cellular response to chemical stress | 188/6293 | 337/18723 | 3.16e-17 | 3.07e-15 | 188 |
GO:004593634 | Thyroid | ATC | negative regulation of phosphate metabolic process | 233/6293 | 441/18723 | 3.68e-17 | 3.47e-15 | 233 |
GO:000193333 | Thyroid | ATC | negative regulation of protein phosphorylation | 186/6293 | 342/18723 | 1.43e-15 | 1.08e-13 | 186 |
GO:004232634 | Thyroid | ATC | negative regulation of phosphorylation | 203/6293 | 385/18723 | 5.30e-15 | 3.53e-13 | 203 |
GO:003459934 | Thyroid | ATC | cellular response to oxidative stress | 158/6293 | 288/18723 | 7.35e-14 | 3.94e-12 | 158 |
GO:003134623 | Thyroid | ATC | positive regulation of cell projection organization | 186/6293 | 353/18723 | 7.99e-14 | 4.23e-12 | 186 |
GO:2001234210 | Thyroid | ATC | negative regulation of apoptotic signaling pathway | 129/6293 | 224/18723 | 1.26e-13 | 6.46e-12 | 129 |
GO:000030234 | Thyroid | ATC | response to reactive oxygen species | 128/6293 | 222/18723 | 1.38e-13 | 7.00e-12 | 128 |
GO:004254233 | Thyroid | ATC | response to hydrogen peroxide | 92/6293 | 146/18723 | 3.12e-13 | 1.46e-11 | 92 |
GO:0097191210 | Thyroid | ATC | extrinsic apoptotic signaling pathway | 125/6293 | 219/18723 | 7.19e-13 | 3.16e-11 | 125 |
GO:000150332 | Thyroid | ATC | ossification | 206/6293 | 408/18723 | 9.23e-13 | 3.95e-11 | 206 |
GO:001063926 | Thyroid | ATC | negative regulation of organelle organization | 179/6293 | 348/18723 | 3.74e-12 | 1.50e-10 | 179 |
GO:005105219 | Thyroid | ATC | regulation of DNA metabolic process | 183/6293 | 359/18723 | 5.97e-12 | 2.30e-10 | 183 |
GO:2001236210 | Thyroid | ATC | regulation of extrinsic apoptotic signaling pathway | 89/6293 | 151/18723 | 1.43e-10 | 4.40e-09 | 89 |
GO:004873233 | Thyroid | ATC | gland development | 210/6293 | 436/18723 | 1.50e-10 | 4.59e-09 | 210 |
GO:001097523 | Thyroid | ATC | regulation of neuron projection development | 212/6293 | 445/18723 | 4.16e-10 | 1.14e-08 | 212 |
Page: 1 2 3 4 5 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
HGF | MET | HGF_MET | HGF | Breast | Healthy |
HGF | MET | HGF_MET | HGF | Cervix | Precancer |
HGF | MET | HGF_MET | HGF | Endometrium | EEC |
HGF | MET | HGF_MET | HGF | Liver | HCC |
HGF | MET | HGF_MET | HGF | Liver | Healthy |
HGF | MET | HGF_MET | HGF | Liver | Precancer |
HGF | MET | HGF_MET | HGF | Lung | IAC |
HGF | MET | HGF_MET | HGF | Prostate | BPH |
HGF | MET | HGF_MET | HGF | Prostate | Healthy |
HGF | MET | HGF_MET | HGF | THCA | Cancer |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HGF | SNV | Missense_Mutation | c.686G>C | p.Gly229Ala | p.G229A | P14210 | protein_coding | deleterious(0) | possibly_damaging(0.672) | TCGA-C5-A3HL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
HGF | SNV | Missense_Mutation | c.343G>C | p.Glu115Gln | p.E115Q | P14210 | protein_coding | tolerated(0.28) | benign(0.352) | TCGA-C5-A3HL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
HGF | SNV | Missense_Mutation | c.251G>A | p.Cys84Tyr | p.C84Y | P14210 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EK-A2RB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
HGF | SNV | Missense_Mutation | c.126N>A | p.Phe42Leu | p.F42L | P14210 | protein_coding | deleterious(0.01) | benign(0.29) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
HGF | SNV | Missense_Mutation | c.550N>A | p.Glu184Lys | p.E184K | P14210 | protein_coding | tolerated(0.7) | probably_damaging(0.997) | TCGA-VS-A8EL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
HGF | SNV | Missense_Mutation | novel | c.2052G>C | p.Met684Ile | p.M684I | P14210 | protein_coding | tolerated(0.55) | benign(0) | TCGA-ZJ-AAXU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
HGF | SNV | Missense_Mutation | rs768451705 | c.782G>A | p.Arg261His | p.R261H | P14210 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A6-2679-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HGF | SNV | Missense_Mutation | c.1172N>T | p.Cys391Phe | p.C391F | P14210 | protein_coding | deleterious(0) | possibly_damaging(0.748) | TCGA-A6-5657-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Ancillary | leucovorin | SD | |
HGF | SNV | Missense_Mutation | c.559N>T | p.Pro187Ser | p.P187S | P14210 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3966-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
HGF | SNV | Missense_Mutation | c.1693N>T | p.Leu565Phe | p.L565F | P14210 | protein_coding | deleterious(0.04) | possibly_damaging(0.851) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | STI571 | IMATINIB MESYLATE | 11439348 | |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | THALIDOMIDE | THALIDOMIDE | 15939924 | |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | ASPIRIN | ASPIRIN | 11981761 | |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | VM-202 | |||
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | Ficlatuzumab | FICLATUZUMAB | ||
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | PROTEOLYTIC ENZYMES | 9502079 | ||
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | antibody | RILOTUMUMAB | RILOTUMUMAB | |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | RESVERATROL | RESVERATROL | 15672869 | |
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | TAK-701 | |||
3082 | HGF | PROTEASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, GROWTH FACTOR, KINASE, ENZYME | FICLATUZUMAB | FICLATUZUMAB |
Page: 1 2 3 |